Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer
Abstract
Even though targeted therapies are available for cancers expressing oncogenic epidermal growth receptor (EGFR) and (or) human EGFR2 (HER2), acquired or intrinsic resistance often confounds therapy success. Common mechanisms of therapy resistance involve activating receptor point mutations and (or) upregulation of signaling downstream of EGFR/HER2 to Akt and (or) mitogen activated protein kinase (MAPK) pathways. However, additional pathways of resistance may exist thus, confounding successful therapy.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 01, 2021
- Source ID
- 10.1186/s12885-021-08366-7
Entities
People
- Angel L. Troche-torres
- Julia Medina-velázquez
- Luis D. Borrero-garcia
- Luis Velazquez
- Maria Del Mar Maldonado
- Nilmary Grafals-ruiz
- Suranganie Dharmawardhane
Organizations
- Foundation for the National Institutes of Health
- National Institute of General Medical Sciences
- National Institutes of Health
- Puerto Rico Science, Technology and Research Trust
- Susan G. Komen for the Cure